GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Cyclically Adjusted Price-to-FCF

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of May. 15, 2024)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alseres Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Alseres Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alseres Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Alseres Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alseres Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Alseres Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Alseres Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2014 is calculated as:

For example, Alseres Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2014 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=-45.333/100.5595*100.5595
=-45.333

Current CPI (Jun. 2014) = 100.5595.

Alseres Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200409 -2,237.000 80.121 -2,807.655
200412 -1,441.000 80.290 -1,804.795
200503 -1,187.500 81.555 -1,464.214
200506 -1,143.500 82.062 -1,401.262
200509 -1,465.500 83.876 -1,757.002
200512 -1,032.000 83.032 -1,249.848
200603 -1,400.000 84.298 -1,670.071
200606 -989.333 85.606 -1,162.152
200609 -952.000 85.606 -1,118.298
200612 -1,952.333 85.142 -2,305.872
200703 -3,660.667 86.640 -4,248.776
200706 -1,727.667 87.906 -1,976.356
200709 -1,020.750 87.964 -1,166.908
200712 -1,053.000 88.616 -1,194.916
200803 -1,068.500 90.090 -1,192.676
200806 -1,140.750 92.320 -1,242.556
200809 -997.500 92.307 -1,086.680
200812 -574.750 88.697 -651.615
200903 -517.600 89.744 -579.977
200906 -492.800 91.003 -544.549
200909 -352.400 91.120 -388.908
200912 -249.200 91.111 -275.042
201003 -190.200 91.821 -208.302
201006 -150.600 91.962 -164.680
201009 -107.000 92.162 -116.750
201012 -100.833 92.474 -109.649
201103 -137.000 94.283 -146.120
201106 -144.833 95.235 -152.931
201109 -85.667 95.727 -89.992
201112 -69.667 95.213 -73.579
201203 -2.333 96.783 -2.424
201206 -57.333 96.819 -59.548
201209 -44.000 97.633 -45.319
201212 -55.167 96.871 -57.268
201303 -116.833 98.209 -119.629
201306 -50.000 98.518 -51.036
201309 -50.167 98.790 -51.066
201312 -64.333 98.326 -65.794
201403 -64.167 99.695 -64.724
201406 -45.333 100.560 -45.333

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alseres Pharmaceuticals  (OTCPK:ALSE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Alseres Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines